AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
申请人:Beijing Adamadle Biotechnology
Limited Liability Company
公开号:EP3640248A1
公开(公告)日:2020-04-22
The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I:
the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.
本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示:
该化合物是表皮生长因子受体(EGFR)激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、其制备方法和在制备抗肿瘤药物中的用途。
Tricyclic modulators of TNF signaling
申请人:AbbVie Inc.
公开号:US10266532B2
公开(公告)日:2019-04-23
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
Aminopyrimidine compound, preparation method therefor and use thereof
申请人:BEIJING ADAMADLE BIOTECHNOLOGY LIMITED LIABILITY COMPANY
公开号:US11352352B2
公开(公告)日:2022-06-07
The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I:
the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.
本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示:
该化合物是表皮生长因子受体(EGFR)激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、制备方法以及在制备抗肿瘤药物中的应用。
TRICYCLIC MODULATORS OF TNF SIGNALING
申请人:AbbVie Inc.
公开号:US20160304517A1
公开(公告)日:2016-10-20
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.